PRGO
Perrigo·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Bearish Engulfing
Ample Liquidity
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRGO
Perrigo Company Plc
A leading provider of over-the-counter healthcare products and specialty pharmaceuticals
The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74
--
Perrigo Company Plc was incorporated under the laws of Ireland on June 28, 2013. The company is committed to bringing consumers "high-quality, affordable care products" to make their lives better. The Company is a leading provider of over-the-counter health and wellness solutions that enhance personal well-being by empowering consumers to proactively prevent or treat self-manageable diseases. The company is also a major manufacturer of generic prescription drug topical products such as creams, lotions, gels and nasal sprays.
Earnings Call
Q2/2025
Estimate EPS0.59
Actual EPS0.57
Estimate Revenue1.08B
Actual Revenue1.06B
Perrigo's Q2 2025: Navigating Contradictions in Infant Formula Market Dynamics and Gross Margin Expectations
Aug 06,2025 11:26
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
PRGO has released its 2025 Q3 earnings. EPS was reported at 0.8, versus the expected 0.77, beating expectations. The chart below visualizes how PRGO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PRGO has released its 2025 Q3 earnings report, with revenue of 1.04B, reflecting a YoY change of -4.06%, and net profit of 7.50M, showing a YoY change of 135.71%. The Sankey diagram below clearly presents PRGO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
